Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs.

Rogawski MA.

Epilepsia. 2013 May;54 Suppl 2:33-40. doi: 10.1111/epi.12182. Review.

2.

Molecular and cellular mechanisms of pharmacoresistance in epilepsy.

Remy S, Beck H.

Brain. 2006 Jan;129(Pt 1):18-35. Epub 2005 Nov 29. Review.

PMID:
16317026
3.

Role of multidrug transporters in pharmacoresistance to antiepileptic drugs.

Löscher W, Potschka H.

J Pharmacol Exp Ther. 2002 Apr;301(1):7-14. Review.

4.

Plasticity of antiepileptic drug targets.

Beck H.

Epilepsia. 2007;48 Suppl 1:14-8. Review.

5.

Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms.

Schmidt D, Löscher W.

Epilepsia. 2005 Jun;46(6):858-77. Review.

6.

The role of common variation in drug transporter genes in refractory epilepsy.

Soranzo N, Goldstein DB, Sisodiya SM.

Expert Opin Pharmacother. 2005 Jul;6(8):1305-12. Review.

PMID:
16013981
7.

The methylation hypothesis of pharmacoresistance in epilepsy.

Kobow K, El-Osta A, Blümcke I.

Epilepsia. 2013 May;54 Suppl 2:41-7. doi: 10.1111/epi.12183. Review.

8.

Association of a synonymous GAT3 polymorphism with antiepileptic drug pharmacoresistance.

Kim DU, Kim MK, Cho YW, Kim YS, Kim WJ, Lee MG, Kim SE, Nam TS, Cho KH, Kim YO, Lee MC.

J Hum Genet. 2011 Sep;56(9):640-6. doi: 10.1038/jhg.2011.73. Epub 2011 Jul 21.

PMID:
21776001
9.

Various pharmacogenetic aspects of antiepileptic drug therapy: a review.

Mann MW, Pons G.

CNS Drugs. 2007;21(2):143-64. Review.

PMID:
17284096
10.

Pharmacoresistance and the role of surgery in difficult to treat epilepsy.

Wiebe S, Jette N.

Nat Rev Neurol. 2012 Dec;8(12):669-77. doi: 10.1038/nrneurol.2012.181. Epub 2012 Sep 11. Review.

PMID:
22964510
11.

ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis.

Haerian BS, Roslan H, Raymond AA, Tan CT, Lim KS, Zulkifli SZ, Mohamed EH, Tan HJ, Mohamed Z.

Seizure. 2010 Jul;19(6):339-46. doi: 10.1016/j.seizure.2010.05.004. Epub 2010 Jun 3. Review.

12.

Pharmacotherapy of epilepsy: new armamentarium, new issues.

Vajda FJ.

J Clin Neurosci. 2007 Sep;14(9):813-23. Epub 2007 Jul 6. Review.

PMID:
17618119
13.

Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected.

Löscher W, Luna-Tortós C, Römermann K, Fedrowitz M.

Curr Pharm Des. 2011;17(26):2808-28. Review.

PMID:
21827408
14.

Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy.

Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D.

Epilepsia. 2001 Dec;42(12):1501-6.

15.

Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions.

Lazarowski A, Czornyj L.

Drug Metabol Drug Interact. 2011;26(1):21-6. doi: 10.1515/DMDI.2011.006. Review.

PMID:
21557674
17.

The puzzle(s) of pharmacoresistant epilepsy.

Pohlmann-Eden B, Weaver DF.

Epilepsia. 2013 May;54 Suppl 2:1-4. doi: 10.1111/epi.12174.

18.

Clinical aspects and biological bases of drug-resistant epilepsies.

Regesta G, Tanganelli P.

Epilepsy Res. 1999 Apr;34(2-3):109-22. Review.

PMID:
10210025
19.

[Drug resistance in epilepsy].

Czuczwar P, Kaczmarczyk K, Wierzchowska-Cioch E, Łuszczki JJ, Czuczwar SJ.

Przegl Lek. 2009;66(11):963-6. Review. Polish.

PMID:
20297639
20.

The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs.

Stępień KM, Tomaszewski M, Tomaszewska J, Czuczwar SJ.

Pharmacol Rep. 2012;64(5):1011-9. Review.

Supplemental Content

Support Center